Kinins exert cardioprotective effects via 2 G-protein-coupled receptors, B 1 and B 2. Using B 1 kinin receptor gene knockout mice (B 1 Ϫ/Ϫ ), we tested the hypotheses that the B 1 receptor plays an important role in preservation of cardiac function, whereas lack of B 1 may accelerate cardiac remodeling and dysfunction after myocardial infarction, and that B 2 receptors may compensate for lack of B 1 , whereas blockade of B 2 receptors in B 1 Ϫ/Ϫ mice may cause further deterioration of cardiac function and remodeling. Female B 1 Ϫ/Ϫ mice and wild-type controls (C57BL/6J, B 1 ϩ/ϩ ) underwent sham surgery or myocardial infarction and were treated with either vehicle or B 2 -antagonist (icatibant, 500 g/kg per day, subcutaneous) for 8 weeks. We found that in sham myocardial infarction, B 1 Ϫ/Ϫ mice had a larger left ventricular diastolic chamber dimension both initially and at 4 to 8 weeks compared with B 1 ϩ/ϩ . Left ventricular mass and myocyte size were also larger in B 1 Ϫ/Ϫ with sham operation than in B 1 ϩ/ϩ , although cardiac function did not differ between strains. After myocardial infarction, cardiac remodeling and function were similar in both strains, although B 1
K inins are vasodilator polypeptides released from lowand high-molecular-weight kininogens by plasma and tissue kallikreins and hydrolyzed by angiotensin-converting enzyme (ACE, also called kininase II), neutral endopeptidase-24.11, and other peptidases. 1, 2 The biological action of kinins is mediated by activation of at least 2 known Gprotein-coupled receptors, B 1 and B 2 . 3,4 B 2 receptors are constitutively expressed in most tissues, whereas B 1 receptors are weakly expressed under physiological conditions but strongly induced in response to pathological stimuli such as inflammation or tissue injury. 5, 6 Recent studies suggest that the B 1 receptor is involved in regulation of vasodilatation, inflammation, and tissue repair, including myocardial infarction. 6 -9 Lamontagne et al 10 reported that activation of the B 1 receptor by intravenous infusion of des-Arg 9 -bradykinin caused a profound hypotensive response, which was partially blocked by the nitric oxide synthase (NOS) inhibitor N Gnitro-L-arginine, suggesting an NO-mediated mechanism. Su et al showed that intracoronary infusion of des-Arg 9bradykinin produced dose-dependent coronary vasodilatation, as evidenced by increased coronary diameter and blood flow; this was not affected by a B 2 kinin receptor antagonist (B 2 -ant) but was attenuated by NOS blockade. 5 Activation of the B 1 receptor has also been shown to promote angiogenesis in vivo and endothelial cell proliferation in vitro through the NOS pathway. 11, 12 Emanueli et al reported that hindlimb ischemia in mice induced B 1 gene overexpression accompanied by increased muscular capillary density, and this angiogenesis was blunted by a B 1 receptor antagonist but unaffected by B 2 blockade. 13 It has also been reported that both B 1 and B 2 receptors are upregulated in the left ventricle (LV) after myocardial infarction (MI). 7 However, the pathophysiological relevance of upregulation of both receptor subtypes remains unclear. We recently showed that mice lacking B 2 kinin receptors (B 2 Ϫ/Ϫ ) did not exhibit altered blood pressure (BP) or cardiac phenotype under normal conditions; however, the therapeutic effect of ACE inhibitors (ACEi) and angiotensin II type 1 receptor antagonists on cardiac dysfunction and remodeling was diminished in B 2
Ϫ/Ϫ mice subjected to MI. 14 
Duka et al 15 reported that the B 1 receptor is upregulated in B 2
Ϫ/Ϫ mice, which exhibited a hypotensive response to a selective B 1 agonist and an acute hypertensive response to a selective B 1 antagonist. In the present study, using mice with targeted deletion of B 1 receptors (B 1 Ϫ/Ϫ ), we further studied whether B 1 receptors play an important role in cardiac remodeling after MI, whether lack of B 1 may accelerate cardiac remodeling and dysfunction after MI, or whether the B 2 receptor may act as a compensatory mechanism for lack of the B 1 receptor. Simultaneous blockade of B 1 and B 2 eliminates this compensation and causes further deterioration of cardiac dysfunction and remodeling after MI.
Materials and Methods

Animals and Procedures
Two breeding pairs of B 1 kinin receptor knockout mice (B Ϫ/Ϫ ) on a C57/J6 genetic background were obtained from Dr Michael Bader's laboratory (Max-Delbrück Center for Molecular Medicine, Berlin-Buch, Germany) 16 and bred in our Mutant Mouse Facilities. Wildtype C57BL/6J ϩ/ϩ purchased from Jackson Laboratories (Bar Harbor, Me) served as controls. Animals were housed in an airconditioned room with a 12-hour light/dark cycle, received standard mouse chow, and drank tap water. For induction of MI, female mice 10 to 12 weeks of age were anesthetized with sodium pentobarbital (50 mg/kg, intraperitoneal). MI was surgically induced by ligating the left anterior descending coronary artery as described previously. 17 This study was approved by the Institutional Animal Care and Use Committee of Henry Ford Health System, and all procedures involving animals were performed in accordance with institutional guidelines.
Measurement of BP and Cardiac Function
Systolic BP (SBP) and heart rate (HR) were measured weekly in conscious mice using a noninvasive computerized tail-cuff system (BP-2000; Visitech Systems, Apex, NC) as described previously. 18, 19 Left ventricular diastolic dimension (LVDd), mass, and shortening fraction (SF), an index of LV systolic performance, were measured monthly with a Doppler echocardiographic system equipped with a 15-MHz linear transducer (Acuson c256, Mountain View, Calif) as described previously. 20, 21 All studies were performed on awake mice.
Histopathological Study
Mice were euthanized after 8 weeks of MI. The heart, lungs, and liver were weighed to assess hypertrophy and congestion. The LV was sectioned transversely into 3 slices from apex to base and rapidly frozen in isopentane precooled in liquid nitrogen, then stored at Ϫ70°C to measure infarct size, myocyte cross-sectional area, interstitial collagen fraction, and oxygen diffusion distance as described previously. 22, 23 
Experimental Protocols
To determine the inhibitory effect of B 2 -ant on the BP response to exogenous bradykinin (BK), B 1 ϩ/ϩ mice received either vehicle or B 2 -ant (icatibant) at 100 or 500 g/kg per day. B 2 -ant was injected daily subcutaneously for 2 weeks. Mice were then anesthetized with sodium pentobarbital (50 mg/kg, IP), placed on a heating pad, and the carotid artery and jugular vein were cannulated to measure mean blood pressure and administer BK (25, 50, and 100 ng/mouse as a bolus) at 15-minute intervals. As shown in Figure 1 , B 2 -ant at 500 g/kg per day almost completely blocked the vasodepressor effect of BK; thus, this dose was chosen for the study.
To determine whether lack of B 1 receptors alters cardiac morphology and function at baseline and after MI, and whether blockade of B 2 receptors causes cardiac function and remodeling to deteriorate further after MI in B 1 Ϫ/Ϫ mice, both B 1 ϩ/ϩ and B 1 Ϫ/Ϫ mice were divided into sham MI; MI plus vehicle; and MI plus B 2 -ant (500 g/kg per day, subcutaneous). Vehicle or B 2 -ant was started 3 days before MI and continued for 8 weeks after MI.
Data Analysis
Data are expressed as meanϮSE. Student's 2-sample t test was used to compare differences between groups, either between strains or between treatments within strains. When multiple comparisons were performed, Hochberg's step-up procedure was used to adjust probability values. 24 The type I error rate was set at 0.05.
Results
Inhibitory Effect of B 2 -ant on Mean BP Response to Bradykinin
We tested the inhibitory effect of B 2 -ant on BK-induced vasodilatation. BK caused dose-dependent reduction of mean blood pressure. B 2 -ant at 100 g/kg per day partially but significantly blocked the vasodilator response to BK, whereas at 500 g/kg per day it almost completely prevented the mean blood pressure response to BK ( Figure 1 ).
Mortality, Tissue Weight, and Infarct Size
Within 24 hours after MI, 4 out of 22 mice died in the B 1 Ϫ/Ϫ vehicle group and none died in the B 1 ϩ/ϩ group (nϭ21), but the difference was not statistically significant. Otherwise, the mortality rate was similar and no cardiac rupture was found in either strain. Body and organ weight in sham MI groups were no different between strains. MI increased LV and total heart weight to a similar extent in both B 1 ϩ/ϩ and B 1 Ϫ/Ϫ but had no effect on lung or liver weight. B 2 -ant increased total heart weight further in B 1
Ϫ/Ϫ compared with B 1 ϩ/ϩ . There was no significant difference in infarct size among groups or between strains (Table) .
SBP and HR
Basal SBP and HR were similar between strains in all groups (Table) . After MI, SBP did not change significantly in B 1 ϩ/ϩ , whereas B 1 Ϫ/Ϫ tended to have lower SBP. B 2 -ant per se had no effect on SBP in either strain. MI did not cause a significant increase in HR in either strain.
Cardiac Function and LV Chamber Dimension
Lack of B 1 receptors had no effect on cardiac performance under basal conditions. LV SF was similar between B 1 ϩ/ϩ and Ϫ/Ϫ compared with vehicle within strains, although the difference was not statistically significant.
Histological Measurements
In sham-operated mice, LV mass, myocyte cross-sectional area, and oxygen diffusion distance were larger in B 1 Ϫ/Ϫ than in B 1 ϩ/ϩ , whereas interstitial collagen fraction was similar between strains ( Figures 5, 6, and 7) . MI increased LV mass, myocyte cross-sectional area, and oxygen diffusion distance to a similar extent in both strains receiving vehicle, whereas collagen deposition was more severe in B 1
Ϫ/Ϫ . The B 2 -ant increased myocyte hypertrophy and oxygen diffusion distance further in B 1 Ϫ/Ϫ and these effects were not seen in B ϩ/ϩ (Figures 5, 6, and 7 ).
Discussion
We found that lack of the B 1 receptor in mice did not affect SBP and cardiac performance under basal conditions. However, B 1 Ϫ/Ϫ with sham MI had larger LV chamber dimension, myocyte size, and LV mass compared with wild-type con- 
trols. The larger LV dimension and myocyte hypertrophy in B 1
Ϫ/Ϫ mice did not have a significant impact on structural and functional remodeling after MI, because LV chamber dilatation, cardiac hypertrophy, and collagen deposition, as well as LV dysfunction, were similar between B 1 ϩ/ϩ and B 1 Ϫ/Ϫ receiving vehicle. Blockade of B 2 receptors tended to cause further reduction of SF and increase in LV dilatation and myocyte hypertrophy in B 1 Ϫ/Ϫ , effects not seen in B 1 ϩ/ϩ . These findings may indicate that the B 1 receptor is involved in regulation of structural homeostasis, because B 1 Ϫ/Ϫ mice had increased heart weight, myocyte size, and LV chamber dimension under basal conditions. However, the B 1 receptor does not seem to play an important role in remodeling after MI, because lack of B 1 did not worsen cardiac function and remodeling compared with wild-type controls. Moreover, B 2 may play a compensatory role for lack of B 1 , because blocking the B 2 receptor tended to exaggerate LV dysfunction and remodeling in B 1 Ϫ/Ϫ .
Evidence indicates that a local or tissue kallikrein-kinin system exists in the heart, because kininogens, kininogenases (kallikreins), and kinins are all found in the heart. 3, 25 The biological actions of kinins are mediated via 2 subtypes of G-protein-coupled receptors, B 1 and B 2 . 3,4 B 2 receptors are constitutively expressed in most tissues and are sensitive to bradykinin and kallidin, whereas B 1 receptors are induced in response to pathological stimuli, such as inflammation or tissue injury, and are sensitive to des-Arg 9 -bradykinin and des-Arg 10 -kallidin, two carboxypeptidase metabolites of kinins. 5, 6 Recent studies have shown that activation of the B 1 receptor by des-Arg 9 -bradykinin causes vasodilator and angiogenic responses via an NO-mediated mechanism. 5, 11 However, the B 1 receptor is only weakly expressed under physiological conditions, and its role in the regulation of cardiovascular homeostasis remains unclear. In the present study, we investigated whether targeted deletion of the B 1 receptor could influence cardiac structure and function under physiological conditions. We found that lack of B 1 receptors did not affect blood pressure and cardiac function in shamoperated mice. However, B 1 Ϫ/Ϫ have an enlarged LV chamber associated with increased LV mass, myocyte size, and oxygen diffusion distance. Collagen deposition tended to be higher in B 1 Ϫ/Ϫ compared with B 1 ϩ/ϩ . These data may suggest that B 1 receptors are involved in maintaining the integrity of cardiac structure. However, the mechanisms responsible for such a response need to be studied further.
It has been shown that B 1 receptors are upregulated in the heart when it is subjected to myocardial ischemia or pressure overload. 7 Using a Langendorff mouse heart preparation, Lagneux et al 26 showed that infarct size was smaller in B 1 Ϫ/Ϫ mice; blockade of B 1 receptors in wild-type controls also reduced ischemic injury, indicating a detrimental effect of the B 1 receptor on cardiac ischemia. However, Agata et al 12 found that local delivery of an adenovirus carrying the kallikrein gene reduced vascular injury caused by balloon angioplasty, as evidenced by reduction of neointima formation and regeneration of endothelium. These effects were blocked by a B 1 antagonist, indicating that activation of B 1 receptors exerts a vascular protective effect. Because B 1 receptors may participate in the inflammatory response and aid in tissue repair and wound healing, 7, 27 in our in vivo study we tested the hypothesis that lack of B 1 receptors may accelerate cardiac remodeling and dysfunction after MI.
However, our data showed that lack of B 1 receptors neither benefits nor deteriorates remodeling after MI. Infarct size, LV function, chamber dilatation, and myocyte hypertrophy were similar between B 1 Ϫ/Ϫ and B 1 ϩ/ϩ , except that collagen deposition was more severe in B 1 Ϫ/Ϫ . Tschöpe et al 7 and Spillmann et al 28 showed that B 1 receptors were induced as early as 6 hours after MI, reached a maximum at 24 hours, decreased to a level comparable to 6 hours MI, and were then weakly expressed until 3 weeks. Early induction of the B 1 receptor may be actively involved in infarct healing and scar formation in the acute phase of MI. However, we are not able to answer this question based on the current study, because this was a chronic experiment and mice were euthanized after 8 weeks MI. Although there were a few more deaths in the B 1 Ϫ/Ϫ group during the first 24 hours after MI, mortality thereafter was similar in both strains. We also saw no deaths caused by cardiac rupture in the first week of MI, which agrees with our previous observation that female mice rarely have rupture. 29 Nevertheless, our findings do not support the hypothesis that lack of B 1 worsens cardiac remodeling after MI.
Duka et al 15 recently reported that the B 1 receptor was upregulated in B 2 Ϫ/Ϫ mice, which exhibited a hypotensive response to a selective B 1 agonist and an acute hypertensive response to a selective B 1 antagonist. We previously showed that lack of B 2 receptors does not alter BP or cardiac phenotype either under normal conditions or after MI. 14, 30 Taken together, these data may indicate a compensatory function of B 1 receptors in maintaining hemodynamic homeostasis when B 2 receptors are absent. Thus, in the present study, we questioned whether dual blockade of B 1 and B 2 worsens cardiac dysfunction and remodeling after MI. Our data showed that in B 1 Ϫ/Ϫ mice, the B 2 -ant icatibant tended to cause further LV dilatation, cardiac hypertrophy, interstitial fibrosis, and reduction of the SF, which were not seen in B 1 ϩ/ϩ controls after 2 months MI. Infarct size was similar among groups, indicating that the effect of B 2 -ant was independent of infarct size. Its effect may primarily involve the viable myocardium. Thus we believe it is essential that at least 1 kinin receptor remain intact, which compensates for functional loss of the other receptor, particularly in pathological conditions such as MI. Inactivation of both B 1 and B 2 eliminates such compensation and leads to further deterioration of cardiac dysfunction and remodeling after MI.
Activation of B 1 receptors may also contribute to the cardioprotective effect of ACEi or angiotensin II receptor blockers. Ignjatovic et al 31, 32 recently reported that the ACEi enalaprilat at nanomolar concentrations directly activated the B 1 receptor in cultured human and bovine endothelial cells, independent of endogenous kinins or ACE activity. This interaction led to prolonged release of NO, which was blocked by a B 1 antagonist but not the B 2 antagonist icatibant. Tschöpe et al 33 showed that the angiotensin II receptor blocker irbesartan improved cardiac function and upregulated B 1 receptors in rats with MI, and this effect was blocked by a B 1 antagonist. However, using an isolated rabbit aorta or mouse stomach preparation, Fortin et al 34 failed to demonstrate that ACEi act as B 1 receptor agonists to stimulate a tissue response. Such controversial findings may call for further studies to clarify the role of the B 1 receptor in the therapeutic effect of ACEi and angiotensin II receptor blockers, particularly in vivo.
Limitations
We demonstrated that blockade of the B 2 receptor worsened cardiac remodeling after MI when B 1 was absent, whereas lack of B 1 per se had no effect on the remodeling process. To confirm the existence of a compensatory mechanism between the 2 kinin receptors, we need to block the B 1 receptor in B 2 knockout mice and see whether cardiac dysfunction and remodeling are aggravated.
Perspectives
A number of studies have shown that both B 1 and B 2 kinin receptors are upregulated in the heart after MI. 7, 35 However, the pathophysiological relevance of kinin receptor upregulation remains unclear. Previously, we have shown that lack of the B 2 receptor did not affect cardiac remodeling after MI. 14 In the present study, we further showed that targeted deletion of B 1 receptors did not aggravate remodeling after MI, whereas blockade of B 2 receptors in B 1 Ϫ/Ϫ mice exaggerated LV dysfunction and remodeling. Taken together, these data may suggest that either B 1 or B 2 compensates for absence of the other receptor. Furthermore, our finding that dual inactivation of B 1 and B 2 (gene deletion plus receptor blockade) caused deterioration of cardiac function and remodeling after MI may indicate that the kallikrein-kinin system acting via the B 1 or B 2 receptor plays an important role in protecting the heart against dysfunction and remodeling after MI. 
